| Company | Value | Change | %Change |
|---|
The company’s revenue surged 44% YoY to ₹440.3 crore, reflecting strong demand for its pharmaceutical products.
Operationally, EBITDA saw a significant jump to ₹76.9 crore compared to ₹15.1 crore in Q3FY24, supported by higher sales and improved cost efficiencies.
AstraZeneca Pharma India, a subsidiary of UK-based AstraZeneca Plc, is engaged in manufacturing, distributing, and marketing pharmaceutical products in India.The company’s EBITDA margin expanded sharply to 17.5% from 4.9% YoY, indicating a strong improvement in profitability.
Also read: Bajaj Healthcare Q3 Results: Swings to profit, revenue jumps 13% on-year
Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.
The company continues to benefit from its global expertise and a strong pipeline of innovative medicines, positioning it well for sustained growth in the Indian market.
